SourceOne Expands Market Presence of Omega-3
SourceOne has partnered with Twin Rivers Technologies (TRT), the world leader in production capacity of Essential Fatty Acids (EFAs), to launch US-produced Omega-3.
10 Nov 2009 --- Increased consumer awareness and demand for the triglyceride form of Omega-3 has engendered the need to expand market access and production capabilities of SourceOne Global Partners’ OmegaChoice Marine Concentrated Omega-3 EPA/DHA.
SourceOne has partnered with Twin Rivers Technologies (TRT), the world leader in production capacity of Essential Fatty Acids (EFAs), to launch US-produced Omega-3. Studies support improved absorption and bioavailability of Omega-3 in the triglyceride form over Omega-3 in the ethyl ester form. TRT’s proprietary Omega-3 technologies and beverage emulsion capabilities provide a strong foundation to meet the growing demand in food, nutritional supplement and pharmaceutical markets for higher Omega-3 EPA and DHA concentrations.
Josipa Paska, Vice President & General Manager of the Health and Wellness Group at Twin Rivers Technologies, said, “The rapidly growing demand for more pure and highly concentrated Omega-3 triglycerides represents a great opportunity for TRT to meet the needs of the quickly evolving trend of choosing Omega-3 triglycerides over ethyl esters. Our expertise in Omega-3 technology and production will enable us to deliver exceptional value in the natural products market place.” According to Paska, TRT’s production capacity is greater than the combined total of all Omega-3 suppliers worldwide.
TRT focuses on Omega-3s in the natural triglyceride form, which is the form of Omega-3 Fatty Acids naturally found in the food we eat. Produced in a Good Manufacturing Practice (cGMP) facility in Cincinnati, OH to pharmaceutical-grade quality standards, TRT’s Omega-3 EFAs contain the highest percentage of EPA and DHA as a triglyceride that is currently available in the global marketplace. “Higher purity and better stability with less odor and fishy taste afford broader applications, consumer appeal, and ultimately consumption,” said Paska.
“The partnership we share with TRT has allowed SourceOne to offer a reliable, superior quality Omega-3 supply with concentrations up to 90% and EPA/DHA ratios that can be customized to meet any formulation specification,” emphasized Jesse Lopez, founder and CEO of SourceOne. “Omega-3 EPA / DHA Essential Fatty Acids are an integral component of our science-based ingredients and formulas. It is paramount that TRT not only has the capability to meet the need for higher concentrations of Omega-3, but also shares our commitment to providing a broad base of applications, unique delivery systems, and the innovation that the market is demanding.”
Lopez adds, “In addition to our unparalleled line up of OmegaChoice concentrated Omega-3 EPA / DHA fish oils; SourceOne has raised the bar for innovation in Omega-3 with the VESIsorb technology. SourceOne has formed an exclusive worldwide partnership with Vesifact AG, Baar, Switzerland, a world leader in drug delivery technology and holder of multiple patents and patents-pending for the VESIsorb naturally self-assembling colloidal delivery systems.”
According to Marc Weder, co-founder and CEO of Vesifact AG, OmegaChoice in the VESIsorb delivery system turns Concentrated Omega-3 EPA/DHA into water-soluble colloidal droplets increasing absorption and broadening the possible applications. “We can offer these benefits with OmegaChoice Concentrated Omega-3 EPA / DHA in either oil form applications or in a powder form for drink mixes, stick packs, beverages, food products and more,” he explained.
SourceOne recently announced the results of a study in humans comparing the absorption and bioavailability of OmegaChoice 90 Concentrated Omega-3 EPA to the same OmegaChoice 90 in the VESIsorb delivery system. The pharmacokinetic pilot study (single oral dose, crossover) demonstrated an increase of 567% in peak blood levels (cmax) of EPA in the formula that utilized the naturally self-assembling VESIsorb delivery system. The relative bioavailability calculated using the area under the curve (AUC0-12h) was also increased by 487%.
Paska adds that TRT is currently planning several new larger studies designed to go beyond pharmacokinetics of absorption and bioavailability that will further demonstrate the many health benefits of OmegaChoice with research focusing on clinical endpoints; e.g. Omega-3 index (RBC EPA + DHA), which is considered a new risk factor for death from CHD.
